Type 1 T cells are the major components in antitumor immunity. The lack of efficient CD8 + cytotoxic T (Tc) cell infiltration of tumors is a major obstacle to adoptive Tc-cell therapy. We have previously demonstrated that adenovirus (AdV)-mediated transgene lymphotactin (Lptn) expression by intratumoral AdVLptn injection and intravenous CD4 + helper T (Th) cell transfer can enhance Tc-cell tumor infiltration and eradication of early stage tumors (5 mm in diameter). In this study, we generated ovalbumin (OVA)-specific Tc1 and Th1 cells in vitro by incubation of OVA-pulsed dendritic cells with naïve T cells from T-cell receptor (TCR) transgenic OT I and OT II mice. We then investigated the potential synergy of Th1 help effect and Lptn transgene expression in Tc1-cell therapy of well-established OVA-expressing EG7 solid tumors (7 mm in diameter). Our data showed that a combined adoptive T-cell therapy of Th1 (2.5 Â 10 6 cells per mouse) and Tc1 (5 Â 10 6 cells per mouse) resulted in regression of all eight (100%) transgene Lptn expressed EG7 tumors, which is significantly higher than four from eight (50%) in AdVLptn/Tc1 group and two from eight (25%) in Tc1/Th1 group (Po0.05). 
Introduction

CD8
+ cytotoxic T (Tc) lymphocytes are a major immunological effector cell population mediating resistance to malignant tumor cells. 1 Effective cancer immunotherapy with adoptively transferred tumor-sensitized Tc cells has resulted in tumor eradication in animal models. [2] [3] [4] [5] Naive CD8 + T cells are precursor cells that do not synthesize any cytokine. When these naive T cells are stimulated by APCs under different culture conditions (IL-12 and anti-IL-4 antibody versus IL-4 and anti-IFN-g antibody), the activated CD8 + Tc cells can be polarized to two effector subsets, Tc1 producing interferon (IFN)-g and Tc2 secreting interlukin (IL)-4 and IL-5, respectively. [6] [7] [8] Both Tc1 and Tc2 demonstrated tumor-specific cytotoxicity in vitro. [9] [10] [11] Dutton et al 12 have originally reported that both tumor-specific Tc1 and Tc2 cells can mediate reduction in lung metastasis of B16 melanoma in vivo. Recently, they have further shown that these tumorspecific Tc1 and Tc2 can also cure intradermally transplanted B16 melanomas, but only in their palpable sizes, 13 but Tc1 cells were more effective than Tc2 in controlling tumor growth and in prolonging the survival times of tumor-bearing mice. 14 
CD4
+ T helper (Th) cells can also be subdivided into two subsets, Th1 producing IL-2 and IFN-g and Th2 secreting IL-4, IL-5 and IL-10. The Th1/Th2 balance has been shown to be critically important in various immune responses including antitumor immunity. 15 It has been reported that Th2 cells responsible for humoral immunity 16 neither enhanced nor suppressed antitumor CD8 + cytotoxic T lymphocyte (CTL) responses. 17 However, Th1 cells essential for the induction of cellular immunity play a major role in priming an antitumor response. 18 For example, in some experiments, in vivo depletion of CD4 + T cells has been shown to facilitate tumor progression; and the cotransfer of CD4 + T cells improves tumor eradication. 19 The traditional explanation is that CD4 + Th1 cells provide IL-2 or helper to CD8 + Tc cells. [21] [22] [23] Recently, it has also been reported that CD4 + Th cells are required in determining the magnitude and persistence of CTL responses 24 and for CD8 + T-cell infiltration of tumors 25 in adoptive Tc-cell therapy. However, the underlying immune mechanisms of CD4 + Th cell effect in adoptive CD8 + Tc-cell therapy are still largely unknown.
The C chemokine lymphotactin (Lptn) was originally reported to induce in vitro migration of T and NK cells, but not monocytes 26 through its interactions with the cellular receptor XCR1. 27 Recently, we have shown that Lptn can also chemoattract neutrophils and B cells expressing XCR1, 28 stimulate tumor-specific CD8 + Tc cell proliferation in vitro and enhance adoptive Tc-mediated therapy of SP2/0 tumors. 19 However, these studies were conducted in treatment of only earlier stage tumors (5 mm in diameter) and in the absence of a known tumor antigen, and therefore lacked capacity to follow the fate of tumor-specific Tc cells in vivo.
Ovalbumin (OVA) is an ideal nominal tumor antigen (Ag) with well-defined MHC class I-and class II-bound epitopes. In this study, we generated a model system using OVA-transfected EG7 tumor cells and the OVAspecific T-cell receptor (TCR) transgenic OT I and OT II mice. These OT I and OT II mice contain the transgenic T-cell receptors (TCRa-V2 and TCRb-V5) recognizing OVA residues 257-264 in the context of H-2K b and OVA residues 323-339 in the context of I-A b , respectively. They have been extensively used to study the specific CD4 + and CD8 + T-cell responses to OVA antigen in vitro and in vivo. [29] [30] [31] The advantage of using these transgenic mice is that they provide a virtually monoclonal source of T cells with known specificity, where the respective roles of OVA-specific CD4 + and CD8 + T cells can be evaluated. Based upon this model, we investigated the potential synergistic effect of combined Th1 help effect and chemokine Lptn transgene expression in Tc1 cell therapy of well-established EG7 solid tumors (7 mm in diameter). In addition, the immune mechanisms involved in this combined Tc1-cell immunotherapy was also elucidated.
Results
Phenotypic characterization of in vitro-generated OVA-specific T-cell subsets Two different T-cell subsets (CD4 + Th1 and CD8 + Tc1 effector cells) were generated in vitro from OVA-specific TCR transgenic OT II and OT I mice, respectively, as described in Materials and methods. Both of the two T-cell subsets displayed their T-cell subset marker (CD4 or CD8), Va2Vb5 + TCR, IL-2 receptor (CD25), active T-cell marker (CD69) and FasL. The expression of IFN-g and IL-4 of these T-cell subsets was further assessed by flow cytometry (intracellular cytokines; Figure 1a ). The secretion of IFN-g, IL-4, TNF-a, IL-2 of these T-cell subsets was further assessed by ELISA (secreted cytokine; Figure 1b) . Following in vitro restimulation, both Th1 and Tc1 populations were stained positively for intracellular IFN-g and secreted abundant IFN-g protein (2.5 and 3.4 ng/ml), TNF-a protein (1.3 and 0.9 ng/ml) and IL-2 protein (1.8 and 1.7 ng/ml) in their culture supernatants. Neither population was stained strongly for intracellular IL-4 by flow cytometric analysis. Both populations did secrete very low levels of IL-4 (relative to their IFN-g responses). This pattern of cytokine expression is consistent with a type 1 immune response usually associated with antitumor immunity, 32 and indicates that these CD4 + and CD8 + populations comprised Th1 and Tc1 phenotype cells, respectively. In addition, all these two T subset populations also expressed large amounts of cell-surface Fas ligand and intracellular perforin (Figure 1a ).
CD8
+ Tc1 effector cells display cytotoxicity to specific target cells in vitro
The in vitro-activated Tc1 cells from OT I mice exhibited strong cytotoxicity for OVA-expressing EG7 tumor cells (88% specific killing at an E:T cell ratio of 1.5) and DC OVA (75% specific killing at an E:T cell ratio of 1.5), but not for the parental EL-4 tumor cells and DCs without OVA expression (Figure 2a) , indicating that the killing activity is OVA-specific. Compared to Tc1, the killing activity of Th1 cells expressing FasL and perforin is relatively lower. As shown in Figure 2c , the cytotoxicities of Th1 cells for LB27 OVAII and DC OVA at an E:T cell ratio of 50 were 34 and 24%, respectively. No cytotoxicity was found for nonspecific target cells DCs and LB27 cells or EG7 tumor cells without Ia b /OVAII complex expression, indicating that the killing activity is OVA-specific. Nearly 90% of CD8 + Tc1 and CD4 + Th1 mediated killing could be blocked using anti-H-2K b and anti-Ia b Abs, respectively (Figure 2b and d) . In general, CTLs kill the target cells through two distinct cytolytic pathways, the perforindependent granule exocytosis and the FasL/Fas interaction pathways. 33 The perforin, in the presence of calcium, has the ability to insert into lipid bilayer membranes, polymerize, and form structural and functional pores that can lead to cell lysis, whereas binding of FasL on CTLs to Fas initiates the death pathway of apoptosis in the Fas-bearing target cells. To study the killing mechanism, CMA and emetin were used to inhibit the perforin-and Fas/FasL interaction-mediated cytotoxicity, respectively. Our data showed that both CMA and emetin demonstrated dose-dependent inhibition of T-cell cytotoxicity (data not shown). The treatment of CMA at 1 mM induced nearly complete inhibition (90-95%) of Tc1 and Th1 mediated cytotoxicity to EG7 tumor cells, while emetin treatment at 5 mM resulted in only around 10% inhibition (Figure 2b and d) , indicating that the perforinmediated pathway plays a major role in both Tc1 and Th1 cytotoxicity.
Reverse transcription-polymerase chain reaction (RT-PCR) analysis of Lptn and Lptn receptor expression
To examine chemokine Lptn expression, RNA extracted from adenovirus-infected EG7 Lptn , EG7 pLpA and untransfected EG7 tumor tissues was subjected to RT-PCR analysis. As shown in Figure 3a , Lptn expressions were found in AdVLptn-transfected EG7 Lptn tumor tissues, but not in the control AdVpLpA-transfected EG7 pLpA and untransfected EG7 tumor tissues, indicating that the AdVLptn is functional. To examine chemokine receptor XCR-1 expression, RNA extracted from OVAspecific CD8 + Tc1 cells and EG7 tumor cells was also subjected to RT-PCR analysis. The XCR-1 expression was seen in the activated CD8 + Tc1 cells, but not EG7 tumor cells, indicating that these Tc1 cells are good targets for Lptn chemotaxis in vivo. Our previous studies have shown that Lptn can chemoattract tumor-specific T cells in vitro.
19,34
To investigate whether the transgene-expressed chemokine Lptn is also chemotactic to the OVA-specific CD8 + Tc1 cells, we conducted in vitro chemotaxis assays by using Boyden microchemotaxis chambers. As shown in Figure  3b , the recombinant Lptn displayed a dose-dependent chemotaxis for CD8 + Tc1 cells in vitro. The protein extract of EG7 Lptn tumor tissues also displayed a strong chemotaxis for the active OVA-specific CD8 + Tc1 cells in vitro, but not the extract of EG7 pLpA tumor tissues. This chemotactic effect could be specifically inhibited by the anti-Lptn Ab, but not by the control rabbit Ab (data not shown), indicating that the transgene-expressed Lptn in AdVLptn-transfected EG7 Lptn tumor tissues is functional.
Additive effect of recombinant Lptn and Th1 cells in proliferation of Tc1 cells in vitro
Since chemokine Lptn is able to chemoattract Tc1 cells, we next examined the impact of Lptn signaling on the proliferative responses on these CD8 + Tc1 cells. We found that the recombinant Lptn had dose-dependent stimulatory effects on these active CD8 + Tc1 cells from OT I mice (Figure 4a ). The stimulatory effect of Lptn was further confirmed by demonstration that the rabbit anti-Lptn Ab blocked 98% of the stimulatory effects of exogenous Lptn on the CD8 + Tc1-cell. Tc1 cell proliferation increased by 50% in presence of Lptn (250 mg/ml). In addition, Th1 cells could also stimulate 19% increase of Tc1 cell proliferation in vitro. Interestingly, a combination of Lptn and Th1 cells displayed an additive effect with 71% increase in proliferation of active CD8 + Tc1 cells (Figure 4b ). + Th1 and CD8 + Tc1 cells were purified from transgenic OT II and OT I mice by negative selection using the CD8 (Ly2)-and CD4 (L3T4)-paramagnetic beads and activated by co-culturing with OVA-pulsed DC OVA for 3 days, respectively, as described in Materials and methods. These activated T cells were stained using a panel of antibodies for analysis of CD4, CD8, CD25, CD69, Vb5.1TCR and FasL expression or permeabilized for analysis of intracellular IL-4, IFN-g and perforin expressing using a commercial kit and PE-conjugated anti-IL-4, IFN-g and perforin Abs (solid lines). Unpermeabilized CD4 + Th1 and CD8 + Tc1 cells were used as negative control cells (dotted lines). One representative experiment of two is shown. (b) These in vitro-activated Th1 and Tc1 cell subsets were restimulated by culturing them with irradiated BL27 OVAII and EG7 tumor cells in RPMI 1640 medium containing 10% FCS for 1 day, then the supernatants were harvested and assayed for IFN-g, IL-4, TNF-a and IL-2 expression by ELISA. The values presented represent the means of triplicate cultures from two distinct experiments.
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Transgene Lptn expression enhances the efficacy of adoptive Tc1-cell therapy Since chemokine Lptn is able to chemoattract Tc1 cells, we next addressed the question on whether transgene Lptn expression can enhance the efficacy of adoptive CD8 + Tc1 T-cell therapy in treatment of well-established tumors (7 mm in diameter). As expected, the tumors within the mice only treated with AdVLptn grew very aggressively ( Figure 5a ) and most of mice in this group died within 30 days subsequent to the tumor inoculation ( Figure 5b ). Of great significance, here, was the observation that four of eight (50%) mice that had been treated with both AdVLptn and had received the adoptive Tc1 cell transfers were entirely tumor-free at 70 days postinoculation of tumor cells. This is significantly higher than those treated with either AdVLptn alone or AdVpLpA plus Tc1 (Log-rank test, Po0.05). These results compellingly demonstrate that transgene (Lptn) expression can enhance antitumor adoptive Tc1 therapy in mice with well-established EG7 tumors, but not completely cure all tumor-bearing mice.
CD4
+ Th1 cells enhance the efficacy of adoptive CD8 + Tc1-cell therapy
As shown in Figure 6a , transfer of CD4 + Th1 cells alone did not affect EG7 tumor growth, though they killed LB27 OVAII and DC OVA expressing Ia b /OVAII complexes ( Figure 2c ). All mice died within 2 weeks subsequent to the CD4 + Th1 cell transfer. This is because both in vitro and in vivo growing EG7 tumor cells did not express Ia b (data not shown). Since CD4 + Th cells are able to enhance adoptive Tc-cell immunotherapy, 19 ,24,25 we next addressed the question on whether the OVA-specific CD4 + Th1 cells can enhance the efficacy of adoptive Tc1-cell therapy of well-established tumors. We repeated these experiments using the in vitro-activated CD8 + Tc1 cells for the passive transfers in combination with of OVA-specific Th1 cells. As shown in Figure 6a and b, the combined therapy resulted in regression of two of eight well-established EG7 tumors. This is significantly efficient than those treated with either Th1 or Tc1 cells (Logrank test, Po0.05), indicating that Th1 cells can enhance Tc1 cell immunotherapy.
Synergistic effect of Lptn transgene expression and Th1 cells in adoptive Tc1-cell therapy
We next wanted to investigate the potential synergistic effect of the above two factors (Th1 and Lptn expression) in adoptive Tc1 cell immunotherapy. We repeated these experiments using the in vitro-activated CD8 + Tc1 cells for the passive transfers in combination with of Th1 cells and Lptn transgene expression. As shown in Figure 7 , the combined adoptive Tc1-cell therapy resulted in regression of all eight transgene (Lptn)-expressed EG7 tumors (100%), indicating that the combined transgene Lptn expression and Th1 cells can synergistically enhance the antitumor immunity of Tc1 cell-mediated immunotherapy than the transgene Lptn expression (50%) or Th1 cells (12.5%) alone (Log-rank test, Po0.05). Furthermore, we found that eight out of eight mice that had rejected such Lptn expressed tumors had all developed solid tumor-specific immunologic memory, such that they also rejected EG7 tumor cell challenges given 8 weeks later. We have previously demonstrated that a local transgene Lptn expression can chemoattract more Tc cells into SP2/0 tumors in vivo. 19 In the study, we repeated these experiments by using the OVA-specific CD8 + Tc1 cells. We directly injected into the tumors with 2 Â 10 9 PFU of AdVLptn. Control mice were given intratumor injections of AdVpLpA. After 1 day, each mouse was then injected intravenous (i.v.) with 5 Â 10 6 CD8 + Tc1 cells labeled with fluorescent cell tracker 5-and 6-carboxylfluorescein diacetate succinimidyl ester (CFSE, 5 mM) (Molecular Probes, Eugene, OR, USA). 31 At 2 days subsequent to injection, mouse tumors were removed. T cells were purified from these tumors, stained with PE-labeled anti-CD8 Ab, and then analyzed by flow cytometry. As shown in Figure 8 , the amount of CFSE-labeled CD8 + Tc1 cells detected in tumors with AdVLptn treatment is 0.22%, which is higher than that in tumors with AdVpLpA (0.09%) or PBS (0.08%) (data not shown) (Student's t-test, Po0.05). Interestingly, CFSE-labeled CD8 + Tc1 cells in tumors with treatment of Th1 is much higher (0.41%) (Student's t-test, Po0.05). As expected, the amount of CD8 + Tc1 cells in tumors with both Th1
and AdVLptn treatments is 0.72%, around eight times more than that of the AdVpLpA-treated tumors, clearly suggesting that CD8 + Tc1 cells were preferentially localizing to the tumors that expressed both Lptn and adoptive CD4 + Th1 cells.
Discussion
CTLs play a crucial role in the host immune responses to cancer. Effective adoptive cancer immunotherapy with tumor-sensitized CTLs has been well documented in animal models, where transfer of such tumor-specific cells into mice bearing tumors resulted in tumor eradication. [1] [2] [3] [4] [5] Recently, Becker et al 35 have also shown that Tc cells enriched through an IFN-g-capture method displayed enhanced cytotoxicity and adoptive tumor therapy. In most of these animal models, however, adoptive Tc-cell therapies are limited in treatment of only early stage tumors (eg, 3-day or palpable tumors + Tc1 cells to recombinant chemokine Lptn (0-100 ng/ml) or EG7 Lptn and EG7 pLpA tumor tissue extract (1 mg/ml) were assessed using 2 h microchemotaxis assays. To confirm the Lptn in EG7 Lptn tumor tissue extract, the anti-Lptn Ab (10 mg/ml) was added to the extract. The results of chemotaxis assays are expressed as the mean number of cells/40 Â field (7s.e.m.). The data comprise one representative experiment of two.
Figure 4 CD8
+ Tc1 cell proliferation assay. In vitro-activated OVAspecific CD8 + Tc1 cells were prepared as described in Figure 1 , and then assessed for their proliferative responses to Lptn signaling using 
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day early lung metastases). In clinical practice, most candidates for cancer therapy are patients with existing tumor burdens. Therefore, if we are to accurately model the clinical cases, we must direct our questions of therapeutic efficacy to the elimination of well-established tumors in experimental animal models. Only limited numbers of patients have responded to T-cell therapy, [36] [37] [38] [39] probably due to only very small fractions of transferred T cells accumulating in tumors and lacking of T-cell helper arm. 18, 40, 41 We have previously demonstrated that CD4 + Th cells enhanced the therapeutic efficacy of Tc cell immunotherapy in treatment of earlier stage SP2/0 tumors (5 mm in diameter). 19 In this study, we selected to work on 10-day well-established EG7 tumors (7 mm in diameter) with well-developed vasculatures. We investigated the potential synergistic effect of combined Th1 help effect and chemiokine Lptn transgene expression in Tc1 cell therapy. Our data showed that these two different T-cell subsets (Th1 and Tc1) derived from transgenic OT II and OT I mice, respectively, all express Va2Vb5 TCR, perforin and FasL. Both of Th1 and Tc1 cells predominantly secreted IFN-g, confirming they are type I T cells. Our data also demonstrated that Tc1 cells displayed significant killing activity against OVA-expressing EG7 tumor cells, but not EL4 tumor cells, indicating the killing activities of Tc1 are OVA-tumor specific. In addition, treatment of CMA induced nearly complete inhibition Tc1-mediated cytotoxicity to EG7 tumor cells, while emetin treatment resulted in only a minimum inhibition, Figure 5 Impact on tumor growth and mortality rates in adoptive Tc1-cell immunotherapy with AdVLptn treatment. Mice bearing 10-day EG7 tumors (Lptn expressed or not) were given i.v. injections of 5 Â 10 6 CD8 + Tc1 (a). Tumor growth was monitored and the tumor size (diameter) measured daily using an engineering caliper. The evolution of the tumors in individual mice is depicted, as are the fractions of mice in each treatment group that were tumor-free at 70 days post-treatment. (b) The readout in this figure represents the long-term mortality among the animals, as determined by daily assessments across 70 days post-treatment. The data closely mirror that in (a), with conclusion that AdvLptn* provide a significant CD8 + Tc1 cell therapeutic advantage over the single use of Tc1 cells alone or Tc1 plus the control AdVpLpA (Log-rank test, Po0.05). One representative experiment of two is shown.
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indicating that the perforin-mediated pathway plays a major role in Tc1 cytotoxicity. The importance to successful Tc-cell immunotherapy of Tc-cell infiltration into target tumor tissues is increasingly being recognized. 5, 42 Tc cell tumor infiltration is the direct relevance to this process of chemokines expressed in the tissues and the receptors for these molecules on the Tc cells, 43 and the chemokine transgene expression enhanced Tc cell infiltration into the tumors. 19 Interestingly, we found that intratumoral injection of AdVLptn enhanced Tc1-cell infiltration of tumors by 2.5-fold in vivo. The enhanced therapeutic effect is likely derived from a combined chemotactic and stimulatory effect of this chemokine for Tc1 cells. Tumor barriers such as the infiltrating stroma may prevent T-cell tumor infiltration. 44 Our results are consistent with a recent report that forced expression of tumor necrosis factor superfamily member (TNFSF-14) in the tumor environment induced a massive infiltration of T cells due to the upregulation of chemokines in tumor environments. 36 Again, consistent with previous reports, 19, 45 we also found that AdVmediated Lptn gene transfer alone did not cure any of the mice that were bearing well-established tumors. Similarly, a combination of the adoptive Tc1-cell transfer with the control AdVpLpA treatment also did not affect tumor eradication. In contrast, the combinational therapy of AdVLptn gene transfer and adoptive Tc1-cell transfer substantially inhibited tumor growth. These results clearly highlight the synergistic therapeutic effects of local expression of Lptn within tumors in the context of adoptive Tc1-cell therapy.
Recently, the cooperative role of CD4 + T cells has been reported for CD8 + CTLs in tumor eradication. 16, 24, 25, 46 In consistent with these reports, our data further showed that combined adoptive transfer of Tc1 cells together with Th1 cells resulted in complete regression of tumors in 2/8 mice, compared to a 0% curing rate seen in a group of tumor-bearing mice with adoptive transfer of Tc1 cells alone, indicating the critical help effect of CD4 + Th1 cells in CD8 + Tc1-cell immunotherapy. Interestingly, we also showed that Th1 cells can stimulate CD8 + Tc1-cell proliferation in vitro. It has been previously reported that the transferred CD8 + T cells alone did not infiltrate the tumors, and they infiltrated into tumors only in the presence CD4 + T cell help by immuno histochemical analysis. 25 Our data clearly demonstrated that more CFSE-labeled CD8 + Tc1 cells (4.5-fold) were detected in EG7 tumors of mice with treatment of CD4 + Th1 than that in mice without any treatment by using a quantitaive mathod of flow cytometry.
More importantly, for the first time, we demonstrated that a synergistic effect of Th1 help effect together with transgene Lptn expression in Tc1 cell tumor localization and immunotherapy of well-established tumors. Much more CFSE-labeled CD8 + Tc1 cells (eight-fold) were detected in EG7 tumors of this group of mice due to the above Lptn transgene expression and Th1 help effect, compared to that in mice treated with AdVpLpA. All eight out of eight mice bearing 10-day EG7 tumors (7 mm in diameter) were cured by this combined Tc1-cell immunotherapy. In addition to enhanced Tc1 cell tumor localization, it has also been shown that CD4
+ T-cell- + T cells, which in turn augments the cytotoxic effector function of these cells. [21] [22] [23] Thus, passive transfer of tumor-specific CD4 + Th1 cells can enhance the ability of host APCs to initiate endogenous CD8 + T-cell responses and thereby also enhance tumor immunity. 47 Tumor-specific CD4 + T cells can also play a major 'postlicensing' role in CTL-mediated antitumor immunity through maintenance of the CTL pool and its function, thereby allowing for augmented CD8 + T-cell infiltration of the tumor. 25 Taken together, our data provide clear evidence of a potent synergy between adoptive CD4 + Th1 cell transfer and AdV-mediated transgene Lptn expression in CD8 + Tc1-cell immunotherapy resulting in 100% cure of well-established tumors. Therefore, this novel therapeutic strategy may become a tool of considerable conceptual interest in the implementation of future clinical objectives. 31 Female C57BL/6 mice (4-6 weeks of age) were obtained from Charles River Laboratories (St Constant, Quebec, Canada). Animal care was in accord with the guidelines of the University of Saskatchewan.
Materials and methods
Preparation of OVA-specific T-cell subsets
OVA-specific CD4 + T and CD8 + T cells were isolated from the spleens and lymph nodes of OT-II and OT-I TCRtransgenic mice, enriched by passage through nylon wool columns, and then, the CD4 + and CD8 + T cells were further fractionated by negative selection using antimouse CD8 (Ly2) and CD4 (L3T4) paramagnetic beads (DYNAL Inc., Lake Success, NY, USA), respectively, according to the manufacturer's protocols. Both were 498% CD4 + Va2Vb5 + and CD8 + Va2Vb5 + T cells by flow cytometric analysis. C57BL/6 bone marrow-derived DCs generated as described previously 48 were loaded with the chicken egg OVA protein (0.1 mg/ml) (DC OVA ) at 371C for overnight, washed three times with phosphatebuffered saline (PBS) and irradiated (4000 rad) before used as APCs. The OVA-specific T-cell subsets (Th1 and Tc1 cells) were further generated according to the protocols as previously described. 13, 16 Briefly, for Th1 and Tc1 effector cells generation, purified naïve CD4 + and CD8 + T cells from OT II and OT I mice (3 Â 10 5 cells/ml) were stimulated with OVA-pulsed DCs (2 Â 10 5 cells/ml) in the presence of IL-2 (20 U/ml), IL-12 (5 ng/ml) and anti-IL-4 antibody (5 mg/ml), respectively. In vitroactivated T-cell subsets including Th1 and Tc1 were harvested after 4 days' culture and purified using Ficoll-Paque (Sigma, St Louis, MO, USA) density gradient centrifugation.
Phenotypic characterization of OVA-specific active T-cell subsets
In phenotypic analysis, the in vitro-activated Th1 and Tc1 cells were incubated with Abs against Vb5.1, 5.2, CD4, CD8, CD25, CD69 and FasL for 1 h on ice, washed with PBS, and then incubated for 1 h on ice with FITCconjugated anti-rat IgG Ab (5 mg/ml). After another three washes with PBS, the above tumor cells and T cells were analyzed by flow cytometry. 19 Isotype-matched monoclonal Abs with irrelevant specificities were used as controls.
Cytokine expression and secretion
To examine the intracellular expression of cytokines, the in vitro-activated Th1 and Tc1 T cells were processed using a commercial kit (Cytofix/CytoPerm Plus with GolgiPlug; Pharmingen, Inc.), and stained with PE-conjugated anti-IL-4, -IFN-g, or -perforin Abs, according to the manufacturers' protocols. Cytokine secretion in the supernatants by the cells was assessed by using the commercial enzyme-linked immunosorbent assay (ELISA) kits (Endogen, Woburn, MA, USA). Briefly, Tc1 and Th1 subsets were re-stimulated by culturing T cells (0.5 Â 10 6 cells/well) in flat-bottom 96-well plates (Costar Corp, Cambridge, MA, USA) with irradiated (6000 rad) EG7 (0.6 Â 10 5 cells/well) 14 and OVAII-pulsed irradiated (4000 rad) LB27 OVAII (0.6 Â 10 5 cells/well), respectively.
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The culture supernatants were harvested at 1 day for measurement of IFN-g, IL-4, tumor necrosis factor (TNF)-a, IL-2 secretion by using ELISA kits. 19 The results were normalized to the recombinant cytokine standard curves.
Tc1 cell cytotoxicity assay
In T-cell cytotoxicity assays, in vitro-activated CD8 + Tc1 were used as effector cells, whereas 51 Cr-labeled EG7, OVA-pulsed DC OVA or control EL-4 tumor cells and DCs were used as target cells. For CD4 + Th1 cells, the OVAIIpeptide-pulsed LB27 OVAII and DC OVA were used as target Th1 and Lptn increase Tc1 adoptive therapy H Huang et al cells, whereas the LB27, EG7 and DCs were used as control target cells. For testing the killing mechanisms, the effector cells were also preincubated with concanamycin A (CMA) (1 mM) and emetin (5 mM) (Sigma, St Louis, MO, USA) for 2 h to prevent perforin (CMA)-or Fas/FasL interaction (emetin)-mediated cytotoxicity. 50 The target cells were radio-labeled by culturing these cells for 1 h in the culture medium in the presence of 50 ml of sodium [
51 Cr]chromate (36 mCi/ml; Amersham, Arlington Heights, IL, USA), then washed thrice with DMEM. Approximately 1 Â 10 4 labeled target cells per triplicate well were mixed with effector cells at various effector (E):target (T) cell ratios, either alone or with anti-H-2K b (15 mg/ml) or anti-Ia b (15 mg/ml) antibody, and then incubated for 6 h. The percentage of specific lysis was calculated as 100 Â ((experimental cpmÀspontaneous cpm)/(maximal cpmÀspontaneous cpm)). Spontaneous cpm release in the absence of effector cells was o10% of specific lysis. The maximal cpm release was determined by lysis of the target cells with 0.25% Triton X-100.
Adenoviral transfection of EG7 tumors in vivo
Our previous study has shown that a single intratumoral injection of an optimal dose of 2 Â 10 9 PFU AdV is able to transfect a maximal amount (45%) of tumor cells in vivo. 48 To transfect EG7 tumors in vivo, 2 Â 10 9 PFU of AdVLptn and the control AdVpLpA were intratumorally injected into EG7 tumors of tumor-bearing mice. One day subsequent to the AdV injection, tumors transfected with AdVLptn (termed EG7 Lptn ) and AdVpLpA (termed EG7 pLpA ) were removed for extraction of RNA and protein as previously described. 48 
RT-PCR analysis
Total RNA was obtained from adenovirus-infected EG7 Lptn or EG7 pLpA tumor tissues and activated OVAspecific CD8 + Tc1 cells. 19 The first-strand cDNA synthesis for the RT-PCR was performed with 5 mg of RNA using a commercial kit (Stratagene, La Jolla, CA, USA), following the manufacturer's instructions. The PCR primers were specific for chemokines Lptn. The sets of PCR primers were used for detection of chemokine expression, including the sense (5 0 atgag acttc tcctc ctg 3 0 ) and antisense (5 0 ttacc cagtc agggt tactg 3 0 ) primers. 19 Another sets of PCR primers were used for detection of chemokine receptor expression, including the sense (5 0 ctcct gtcta ctgcc tgtgt tg 3 0 ) and anti-sense (5 0 tgact gttcg gtgtc tctgt ct 3 0 ) primers for XCR-1. 19 In addition, another one set of primers was also used, including the sense (5 0 caggt tgtct cctgc gactt 3 0 ) and anti-sense (5 0 cttgc tcagt gtcct tgctg 3 0 ) primers for the control gene glyceraldehyde phosphate dehydrogenase (GAPDH). The PCR conditions comprised one cycle at 941C (5 min), 541C (1 min), and 721C (1 min) and 25 cycles at 941C (1 min), 551C (1 min), and 721C (1 min). All PCR reaction products were resolved on 1% agarose gels with ethidium bromide staining.
Chemotaxis assay
The chemotactic response of activated CD8 + Tc1 lymphocytes to Lptn was examined using modified Boyden microchemotaxis chambers (Neuroprobe, Gaithersburg, MD, USA) and polyvinyl pyrolidone-free 5-mm pore-size polycarbonate membranes, essentially as previously described. 19 Briefly, recombinant Lptn, diluted in DMEM/0.1% bovine serum albumin (BSA) to 0.1-100 ng/ml and protein extracts of EG7 Lptn and EG7 pLpA tumor tissues (1 mg/ml) were added to triplicate lower chambers of the wells, respectively, and 1 Â 10 5 active CD8 + Tc1 lymphocytes in DMEM/BSA were added to the upper chambers. To confirm Lptn in protein extract of EG7 Lptn tumor tissues, protein extract of EG7 Lptn tumor tissues plus rabbit anti-Lptn Ab or the control normal rabbit serum (10 mg/ml) were added to the lower chambers. After incubation for 2 h at 371C, the cells that had not migrated into the membranes were wiped from the upper surfaces of the membranes, which were then fixed in 70% methanol and stained using a Diff-Quik kit (American Scientific Products, McGraw Hill, IL, USA). The lymphocytes that were associated with the membranes were enumerated by direct counting in a blinded fashion of at least nine Â 40 objective fields per well. The results are expressed as the mean number of cells/ Â 40 field (7s.e.m.).
T-cell proliferation assay
Activated CD8 + Tc1 cells were incubated at 0.5 Â 10 6 cells/well in DMEM containing 10% FCS in flat-bottom 96-well plates, alone and with either the recombinant Lptn (125-1000 ng/ml) or irradiated (4000 rad) Th1 cells (0.5 Â 10 6 cells/well) or Lptn (250 ng/ml) plus irradiated Th1 cells, respectively. To confirm the specificity of the Lptn proliferative effect on the T cells, the rabbit anti-Lptn Ab or the control normal rabbit serum (10 mg/ml) was added to each set of wells. After 48 h, all wells were pulsed for 18 h with 1 mCi of [ 
Assessment of Tc1 cell tumor localization in vivo
Detection of transferred CD8 + Tc1 cell tumor infiltration in vivo was performed as previously described. 19 Briefly, on day 0, we intratumorally injected 2 Â 10 9 PFU of AdVLptn and the control AdVpLpA or PBS into wellestablished (ie 12-day) EG7 tumors in the right and left thighs, respectively, of the mice. The next day, the in vitro activated CD8 + Tc1 cells were labeled with CFSE according to the manufacturer's instruction. After three washes with PBS, CFSE-labeled CD8 injected into these tumor-bearing mice. At 2 days subsequent to the T-cell injection, the tumor-bearing mice were killed. Their tumor tissues were removed. Cell suspensions were prepared from these EG7 tumors by mincing them into small pieces and pressing them through a fine mesh. 25 Red cells were lysed by using 0.84% ammonium chloride. T cells were then purified from these cell suspensions by using the CD3 MACS beads (Mittenyi Biotec, Aubum, CA, USA), stained using PE-labeled anti-CD8 Ab, and analyzed by flow cytometry.
Adoptive Tc1 cell immunotherapy model C57BL/6 mice (eight per group) received subcutaneous injections of 1 Â 10 6 EG7 tumor cells in their thighs. To study the effect of Lptn transgene expression, at 12 days postinoculation, when the tumors were B7 mm in 6 Th1 cells. To study the combined effect of Lptn transgene expression and Th1 help effect, when the tumors were B7 mm in diameter, each mouse received an intratumoral injection of 2 Â 10 9 PFU of AdVLptn or the control AdVpLpA. After 1 day, each mouse was further injected i.v. with 5 Â 10 6 Tc1 and/or 2.5 Â 10 6 Th1 T cells. Animal mortality and tumor growth or regression were monitored daily for up to 10 weeks; for humanitarian reasons, all mice with tumors that achieved a size of 1.5 cm in diameter were killed. In experiments to examine the antitumor immune memory, mice cured of their tumors by these means were again challenged with 1 Â 10 6 EG7 tumor cells 8 weeks subsequent to the tumor regression. The tumor growth was then monitored as above. Log-rank test and Graphpad Prism software were used to compare the mouse survival data. 51 
